TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Rhea-AI Summary

TG Therapeutics, Inc. (TGTX) will host a conference call on February 28, 2024, to discuss fourth-quarter and year-end 2023 results and provide a business outlook for 2024. The call will be led by Michael S. Weiss, Chairman, and CEO. Participants can join via phone or webcast. Financial results will be released in a press release before the call.

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, February 28, 2024, at 8:30 AM ET to discuss results for the fourth quarter and year-end 2023 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Fourth Quarter and Year End Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI^® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

 

FAQ

When is TG Therapeutics hosting a conference call to discuss financial results?

TG Therapeutics will host a conference call on February 28, 2024, at 8:30 AM ET to discuss fourth-quarter and year-end 2023 results and provide a business outlook for 2024.

Who will lead the conference call for TG Therapeutics?

Michael S. Weiss, Chairman, and CEO of TG Therapeutics will host the conference call.

How can participants join the conference call?

Participants can join the conference call by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) and accessing the live webcast on the Company's website.

Where can the audio recording of the conference call be accessed?

The audio recording of the conference call will be available for replay at www.tgtherapeutics.com for a period of 30 days after the call.

Where will TG Therapeutics release its financial results?

TG Therapeutics will announce its financial results for the period in a press release issued before the conference call.